Recommend to a friend

Innovator or Biosimilar for a Patient with Ulcerative Colitis?

Upon completion of the activity, participants should be able to: 1. Explain to patients and peers the scientific rationale and empirical data with biosimilars that make them as safe and effective as their biologic originators for inflammatory bowel disease 2. Explain the circumstances under which it is appropriate to initiate or switch a patient with inflammatory bowel disease to a biosimilar